Questa traduzione è in preparazione. Nel frattempo mostriamo temporaneamente la versione originale in inglese.
Imprese · 12/10/20171 min di lettura
Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment; Draft Guidance for Industry; Availability
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment." The purpose of this draft guidance is to assist sponsors in all phases of antiviral drug development for prophylaxis and treatment of disease caused by respiratory syncytial virus (RSV) infection.
Lingua originale della fonte: Federal Register — Food and Drug AdministrationApri il comunicato originale →